Literature DB >> 32870330

DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.

Amina Jamal Laham1,2, Maha Saber-Ayad3,4, Raafat El-Awady5,6.   

Abstract

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a dual kinase that can phosphorylate its own activation loop on tyrosine residue and phosphorylate its substrates on threonine and serine residues. It is the most studied member of DYRK kinases, because its gene maps to human chromosome 21 within the Down syndrome critical region (DSCR). DYRK1A overexpression was found to be responsible for the phenotypic features observed in Down syndrome such as mental retardation, early onset neurodegenerative, and developmental heart defects. Besides its dual activity in phosphorylation, DYRK1A carries the characteristic of duality in tumorigenesis. Many studies indicate its possible role as a tumor suppressor gene; however, others prove its pro-oncogenic activity. In this review, we will focus on its multifaceted role in tumorigenesis by explaining its participation in some cancer hallmarks pathways such as proliferative signaling, transcription, stress, DNA damage repair, apoptosis, and angiogenesis, and finally, we will discuss targeting DYRK1A as a potential strategy for management of cancer and neurodegenerative disorders.

Entities:  

Keywords:  53BP1; Alzheimer; Cancer therapy; Carcinogenesis; DNA damage; DNA repair; RNF169; p53

Year:  2020        PMID: 32870330     DOI: 10.1007/s00018-020-03626-4

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  143 in total

Review 1.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

Review 2.  DNA-damage repair; the good, the bad, and the ugly.

Authors:  Razqallah Hakem
Journal:  EMBO J       Date:  2008-02-20       Impact factor: 11.598

Review 3.  Homologous recombination and the repair of DNA double-strand breaks.

Authors:  William Douglass Wright; Shanaya Shital Shah; Wolf-Dietrich Heyer
Journal:  J Biol Chem       Date:  2018-03-29       Impact factor: 5.157

4.  Induction and repair of DNA double-strand breaks using constant-field gel electrophoresis and apoptosis as predictive markers for sensitivity of cancer cells to cisplatin.

Authors:  Ekram M Saleh; Raafat A El-Awady; Noha Anis; Nahla El-Sharkawy
Journal:  Biomed Pharmacother       Date:  2012-08-19       Impact factor: 6.529

5.  dDYRK2 and Minibrain interact with the chromatin remodelling factors SNR1 and TRX.

Authors:  Ross Kinstrie; Pamela A Lochhead; Gary Sibbet; Nick Morrice; Vaughn Cleghon
Journal:  Biochem J       Date:  2006-08-15       Impact factor: 3.857

6.  Modulation of DNA damage response and induction of apoptosis mediates synergism between doxorubicin and a new imidazopyridine derivative in breast and lung cancer cells.

Authors:  Raafat A El-Awady; Mohammad H Semreen; Maha M Saber-Ayad; Farhan Cyprian; Varsha Menon; Taleb H Al-Tel
Journal:  DNA Repair (Amst)       Date:  2015-11-04

7.  Targeting DNA double-strand break repair: is it the right way for sensitizing cells to 5-fluorouracil?

Authors:  Raafat A El-Awady; Ekram M Saleh; Jochen Dahm-Daphi
Journal:  Anticancer Drugs       Date:  2010-03       Impact factor: 2.248

Review 8.  Kinase-targeted cancer therapies: progress, challenges and future directions.

Authors:  Khushwant S Bhullar; Naiara Orrego Lagarón; Eileen M McGowan; Indu Parmar; Amitabh Jha; Basil P Hubbard; H P Vasantha Rupasinghe
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

9.  Mutational analysis of two residues in the DYRK homology box of the protein kinase DYRK1A.

Authors:  Esti Wahyu Widowati; Simone Bamberg-Lemper; Walter Becker
Journal:  BMC Res Notes       Date:  2018-05-15

Review 10.  Emerging Roles of DYRK Kinases in Embryogenesis and Hedgehog Pathway Control.

Authors:  Rajeev Singh; Matthias Lauth
Journal:  J Dev Biol       Date:  2017-11-21
View more
  14 in total

Review 1.  WNT Signalling in Osteoarthritis and Its Pharmacological Targeting.

Authors:  Anna De Palma; Giovanna Nalesso
Journal:  Handb Exp Pharmacol       Date:  2021

2.  Selective Macrocyclic Inhibitors of DYRK1A/B.

Authors:  Chelsea E Powell; John M Hatcher; Jie Jiang; Prasanna S Vatsan; Jianwei Che; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2022-03-08       Impact factor: 4.632

3.  Differential DNA Methylation in Prostate Tumors from Puerto Rican Men.

Authors:  Gilberto Ruiz-Deya; Jaime Matta; Jarline Encarnación-Medina; Carmen Ortiz-Sanchéz; Julie Dutil; Ryan Putney; Anders Berglund; Jasreman Dhillon; Youngchul Kim; Jong Y Park
Journal:  Int J Mol Sci       Date:  2021-01-13       Impact factor: 5.923

Review 4.  Interplay Between CMGC Kinases Targeting SR Proteins and Viral Replication: Splicing and Beyond.

Authors:  Florentin Pastor; Lulzim Shkreta; Benoit Chabot; David Durantel; Anna Salvetti
Journal:  Front Microbiol       Date:  2021-03-29       Impact factor: 5.640

Review 5.  Emerging roles of DYRK2 in cancer.

Authors:  Vasudha Tandon; Laureano de la Vega; Sourav Banerjee
Journal:  J Biol Chem       Date:  2021-01-07       Impact factor: 5.157

6.  Targeting DYRK1A/B kinases to modulate p21-cyclin D1-p27 signalling and induce anti-tumour activity in a model of human glioblastoma.

Authors:  Andrew J Massey; Karen Benwell; Mike Burbridge; Andras Kotschy; David Lee Walmsley
Journal:  J Cell Mol Med       Date:  2021-10-28       Impact factor: 5.310

7.  DYRK1A Overexpression in Mice Downregulates the Gonadotropic Axis and Disturbs Early Stages of Spermatogenesis.

Authors:  Rodolphe Dard; Manon Moreau; Estelle Parizot; Farah Ghieh; Leslie Brehier; Nadim Kassis; Valérie Serazin; Antonin Lamaziere; Chrystèle Racine; Nathalie di Clemente; François Vialard; Nathalie Janel
Journal:  Genes (Basel)       Date:  2021-11-16       Impact factor: 4.096

8.  DYRK1A suppression attenuates HIF‑1α accumulation and enhances the anti‑liver cancer effects of regorafenib and sorafenib under hypoxic conditions.

Authors:  Chong Zhang; Lin-Wen Wu; Zhi-Di Li; Man-Man Zhang; Jie Wu; Fei-Hua Du; Ling-Hui Zeng; Yang-Ling Li
Journal:  Int J Oncol       Date:  2022-03-04       Impact factor: 5.650

Review 9.  Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.

Authors:  Mattias F Lindberg; Laurent Meijer
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

10.  CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer.

Authors:  Bin Lan; Siyuan Zeng; Shuman Zhang; Xiaofan Ren; Yuming Xing; Isabella Kutschick; Susanne Pfeffer; Benjamin Frey; Nathalie Britzen-Laurent; Robert Grützmann; Nils Cordes; Christian Pilarsky
Journal:  Cancers (Basel)       Date:  2022-01-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.